Karin Berghoff

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel, Ahmad Awada, Maja J.A. de Jonge et al. · British Journal of Cancer · 2020 · 127 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Tepotinib Treatment in Patients With <i>MET</i> Exon 14–Skipping Non–Small Cell Lung Cancer

Julien Mazières, Paul K. Paik, Marina Chiara Garassino et al. · JAMA Oncology · 2023 · 94 citations · Full text

Medicine, Oncology, Pharmacology +13

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 86 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

Baek‐Yeol Ryoo, Ann‐Lii Cheng, Zhenggang Ren et al. · British Journal of Cancer · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i> -Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia et al. · Clinical Cancer Research · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacotherapy +17